144 related articles for article (PubMed ID: 27318562)
1. Methyltransferase inhibitors for modulation of the epigenome and beyond.
Schapira M; Arrowsmith CH
Curr Opin Chem Biol; 2016 Aug; 33():81-7. PubMed ID: 27318562
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in developing selective inhibitors of protein methyltransferases.
Kaniskan HÜ; Jin J
Curr Opin Chem Biol; 2017 Aug; 39():100-108. PubMed ID: 28662389
[TBL] [Abstract][Full Text] [Related]
4. A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.
Scheer S; Ackloo S; Medina TS; Schapira M; Li F; Ward JA; Lewis AM; Northrop JP; Richardson PL; Kaniskan HÜ; Shen Y; Liu J; Smil D; McLeod D; Zepeda-Velazquez CA; Luo M; Jin J; Barsyte-Lovejoy D; Huber KVM; De Carvalho DD; Vedadi M; Zaph C; Brown PJ; Arrowsmith CH
Nat Commun; 2019 Jan; 10(1):19. PubMed ID: 30604761
[TBL] [Abstract][Full Text] [Related]
5. Methyltransferase Inhibitors: Competing with, or Exploiting the Bound Cofactor.
Ferreira de Freitas R; Ivanochko D; Schapira M
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817960
[TBL] [Abstract][Full Text] [Related]
6. (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells.
Barsyte-Lovejoy D; Li F; Oudhoff MJ; Tatlock JH; Dong A; Zeng H; Wu H; Freeman SA; Schapira M; Senisterra GA; Kuznetsova E; Marcellus R; Allali-Hassani A; Kennedy S; Lambert JP; Couzens AL; Aman A; Gingras AC; Al-Awar R; Fish PV; Gerstenberger BS; Roberts L; Benn CL; Grimley RL; Braam MJ; Rossi FM; Sudol M; Brown PJ; Bunnage ME; Owen DR; Zaph C; Vedadi M; Arrowsmith CH
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12853-8. PubMed ID: 25136132
[TBL] [Abstract][Full Text] [Related]
7. Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes: a patent evaluation (WO2012075381).
Lipka DB; Kuck D; Kliem C; Gerhauser C
Expert Opin Ther Pat; 2013 Apr; 23(4):537-43. PubMed ID: 23448241
[TBL] [Abstract][Full Text] [Related]
8. Recently discovered EZH2 and EHMT2 (G9a) inhibitors.
Soumyanarayanan U; Dymock BW
Future Med Chem; 2016 Sep; 8(13):1635-54. PubMed ID: 27548656
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in the discovery of epigenetic inhibitors for the treatment of cancer.
Verma SK
Methods Mol Biol; 2015; 1238():677-88. PubMed ID: 25421686
[TBL] [Abstract][Full Text] [Related]
10. A novel arginine methyltransferase inhibitor with cellular activity.
Spannhoff A; Machmur R; Heinke R; Trojer P; Bauer I; Brosch G; Schüle R; Hanefeld W; Sippl W; Jung M
Bioorg Med Chem Lett; 2007 Aug; 17(15):4150-3. PubMed ID: 17570663
[TBL] [Abstract][Full Text] [Related]
11. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.
Yu W; Chory EJ; Wernimont AK; Tempel W; Scopton A; Federation A; Marineau JJ; Qi J; Barsyte-Lovejoy D; Yi J; Marcellus R; Iacob RE; Engen JR; Griffin C; Aman A; Wienholds E; Li F; Pineda J; Estiu G; Shatseva T; Hajian T; Al-Awar R; Dick JE; Vedadi M; Brown PJ; Arrowsmith CH; Bradner JE; Schapira M
Nat Commun; 2012; 3():1288. PubMed ID: 23250418
[TBL] [Abstract][Full Text] [Related]
12. Challenges in profiling and lead optimization of drug discovery for methyltransferases.
Horiuchi KY
Drug Discov Today Technol; 2015 Nov; 18():62-8. PubMed ID: 26723894
[TBL] [Abstract][Full Text] [Related]
13. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
14. Selective inhibitors of protein methyltransferases.
Kaniskan HÜ; Konze KD; Jin J
J Med Chem; 2015 Feb; 58(4):1596-629. PubMed ID: 25406853
[TBL] [Abstract][Full Text] [Related]
15. Targeting epigenetic machinery: Emerging novel allosteric inhibitors.
Ye F; Huang J; Wang H; Luo C; Zhao K
Pharmacol Ther; 2019 Dec; 204():107406. PubMed ID: 31521697
[TBL] [Abstract][Full Text] [Related]
16. In Situ Proteome Profiling and Bioimaging Applications of Small-Molecule Affinity-Based Probes Derived From DOT1L Inhibitors.
Zhu B; Zhang H; Pan S; Wang C; Ge J; Lee JS; Yao SQ
Chemistry; 2016 Jun; 22(23):7824-36. PubMed ID: 27115831
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic drug discovery: a success story for cofactor interference.
Ganesan A
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685973
[TBL] [Abstract][Full Text] [Related]
19. Targeting epigenetic enzymes for drug discovery.
Copeland RA; Olhava EJ; Scott MP
Curr Opin Chem Biol; 2010 Aug; 14(4):505-10. PubMed ID: 20621549
[TBL] [Abstract][Full Text] [Related]
20. DNA methyltransferases in hematologic malignancies.
Li KK; Luo LF; Shen Y; Xu J; Chen Z; Chen SJ
Semin Hematol; 2013 Jan; 50(1):48-60. PubMed ID: 23507483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
